Lb Pharmaceuticals reported cash from operations of -$37.62M and free cash flow of -$37.98M for the quarter ended Jun 2026, down 571.3% year over year. This cash flow statement covers 8 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -14.18M | -5.07M | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M | -51.60M |
| Share-based Compensation | 0.47M | 0.69M | 0.63M | 0.33M | 26.00M | 2.34M | 3.03M | 36.10M |
| Cash from Operations | -5.67M | -8.13M | -5.60M | -3.37M | -18.10M | -23.30M | -37.62M | |
| Depreciation, Depletion & Amortization | ||||||||
| Amortizatization of Intangibles | 0.06M | 0.01M | -0.26M | -0.02M | -0.02M | 0.07M | ||
| Change in Working Capital | ||||||||
| Change in Accured Expenses | -2.92M | -2.89M | -1.55M | 1.57M | 1.97M | 3.46M | 12.54M | |
| Other Working Capital Changes | -0.01M | -0.08M | -0.24M | 1.37M | 11.30M | 10.22M | 4.07M | |
| Investing Activities | ||||||||
| Capital Expenditures | 0.24M | 0.02M | -0.01M | 0.04M | 0.03M | 0.36M | ||
| Change in Acquisitions & Divestments | 7.26M | 2.50M | 10.20M | |||||
| Cash from Investing Activities | 13.54M | 4.98M | 0.01M | -44.84M | -0.04M | -0.03M | 0.09M | |
| Financing Activities | ||||||||
| Other financing activities | 327.75M | 100.00M | ||||||
| Change in Capital Stock | ||||||||
| Net Shares Issued and Repurchased | 2.21M | 0.47M | ||||||
| Misc. | ||||||||
| Cash from Financing Activities | 303.73M | -1.17M | 93.83M | -0.02M | ||||
| Change in Cash | 7.87M | -3.15M | -5.59M | 255.52M | -19.31M | 70.51M | -37.56M | |
| Free Cash Flow | -5.90M | -8.15M | -5.59M | -3.37M | -18.14M | -23.33M | -37.98M | |
| Net Cash Flow | 7.87M | -3.15M | -5.59M | 255.52M | -19.31M | 70.50M | -37.55M |